Showing results (171-180 of 214) with videos related to
Sort By:
Pageof 22
Journal of Visualized Experiments : Jove|May 1, 2013
Multi-analyte biochip (MAB) based on all-solid-state ion-selective electrodes (ASSISE) for physiological researchWan W Amani Wan Salim, Michael A Zeitchek, Andrew C Hermann, et al.Gastroenterology|June 26, 2016
Detection of Hot-Spot Mutations in Circulating Cell-Free DNA From Patients With Intraductal Papillary Mucinous Neoplasms of the PancreasAndreas W Berger, Daniel Schwerdel, Ivan G Costa, et al.Journal of Cardiac Surgery|January 11, 2019
Evaluation of the safety and efficacy of a new hemostatic powder using a quantitative surface bleeding severity scaleAbbas Ardehali, William D Spotnitz, Rachel W Hoffman, et al.ACS Medicinal Chemistry Letters|September 24, 2015
Fragment-Based Drug Design of Novel Pyranopyridones as Cell Active and Orally Bioavailable Tankyrase InhibitorsJavier de Vicente, Parcharee Tivitmahaisoon, Pamela Berry, et al.International Journal of Cancer|September 15, 2020
Nintedanib plus mFOLFOX6 as second-line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo-controlled, phase II TRICC-C study (AIO-KRK-0111)Thomas J Ettrich, Lukas Perkhofer, Thomas Decker, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 23, 2015
Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancerDavid R Spigel, Jyoti D Patel, Craig H Reynolds, et al.Structure (London, England : 1993)|October 4, 2025
Structural basis for DCAF2 as a novel E3 ligase for PROTAC-mediated targeted protein degradationEvan J McMahon, Alexander G Cioffi, Patrick R Visperas, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2012
A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancerJordan Berlin, Johanna C Bendell, Lowell L Hart, et al.Nature Communications|August 22, 2023
Extending the coherence of spin defects in hBN enables advanced qubit control and quantum sensingRoberto Rizzato, Martin Schalk, Stephan Mohr, et al.Stem Cells International|July 9, 2019
MEK Inhibition Targets Cancer Stem Cells and Impedes Migration of Pancreatic Cancer Cells <i>In Vitro</i> and <i>In Vivo</i>Karolin Walter, Kanishka Tiwary, Marija Trajkovic-Arsic, et al.Pageof 22